AU2017226004B2 - Inhibitors of WDR5 protein-protein binding - Google Patents
Inhibitors of WDR5 protein-protein binding Download PDFInfo
- Publication number
- AU2017226004B2 AU2017226004B2 AU2017226004A AU2017226004A AU2017226004B2 AU 2017226004 B2 AU2017226004 B2 AU 2017226004B2 AU 2017226004 A AU2017226004 A AU 2017226004A AU 2017226004 A AU2017226004 A AU 2017226004A AU 2017226004 B2 AU2017226004 B2 AU 2017226004B2
- Authority
- AU
- Australia
- Prior art keywords
- fluoro
- phenyl
- carboxamide
- pyridine
- trifluoromethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 0 CN(CC1)CCN1c(c(NC(C(C(*)=C1)=CNC1=O)=O)c1)cc(F)c1-c1cnc(N2CCOCC2)nc1 Chemical compound CN(CC1)CCN1c(c(NC(C(C(*)=C1)=CNC1=O)=O)c1)cc(F)c1-c1cnc(N2CCOCC2)nc1 0.000 description 1
- NXSYJUANRFWWGT-UHFFFAOYSA-N CN(CC1)CCN1c(c(NC(C(C(C(F)(F)F)=C1)=CNC1=O)=O)c1)cc(F)c1-c(c(OC)n1)cnc1OC Chemical compound CN(CC1)CCN1c(c(NC(C(C(C(F)(F)F)=C1)=CNC1=O)=O)c1)cc(F)c1-c(c(OC)n1)cnc1OC NXSYJUANRFWWGT-UHFFFAOYSA-N 0.000 description 1
- KCOMOZYHSDZIRW-UHFFFAOYSA-N CN(CC1)CCN1c(c(NC(C(C(C(F)(F)F)=C1)=CNC1=O)=O)c1)cc(F)c1-c(cc1)cnc1NC1CCCCC1 Chemical compound CN(CC1)CCN1c(c(NC(C(C(C(F)(F)F)=C1)=CNC1=O)=O)c1)cc(F)c1-c(cc1)cnc1NC1CCCCC1 KCOMOZYHSDZIRW-UHFFFAOYSA-N 0.000 description 1
- XXSLMFWASLUDIS-UHFFFAOYSA-N CN(CC1)CCN1c(c(NC(C(C(C(F)(F)F)=C1)=CNC1=O)=O)c1)cc(F)c1-c(cn1)cnc1O Chemical compound CN(CC1)CCN1c(c(NC(C(C(C(F)(F)F)=C1)=CNC1=O)=O)c1)cc(F)c1-c(cn1)cnc1O XXSLMFWASLUDIS-UHFFFAOYSA-N 0.000 description 1
- YIGUOFOBBBPQLX-UHFFFAOYSA-N CN(CC1)CCN1c(c(NC(C(C(C(F)(F)F)=C1)=CNC1=O)=O)c1)cc(F)c1-c(cn1)cnc1OCC(F)(F)F Chemical compound CN(CC1)CCN1c(c(NC(C(C(C(F)(F)F)=C1)=CNC1=O)=O)c1)cc(F)c1-c(cn1)cnc1OCC(F)(F)F YIGUOFOBBBPQLX-UHFFFAOYSA-N 0.000 description 1
- XQYUXUMOTAMLEA-UHFFFAOYSA-N CN(CC1)CCN1c(c(NC(C(C(C(F)(F)F)=C1)=CNC1=O)=O)c1)cc(F)c1-c(cn1)cnc1OCCCN(CC1)CCN1c(c(NC(C(C(C(F)(F)F)=C1)=CNC1=O)=O)c1)cc(F)c1-c1cnc(N2CCCC2)nc1 Chemical compound CN(CC1)CCN1c(c(NC(C(C(C(F)(F)F)=C1)=CNC1=O)=O)c1)cc(F)c1-c(cn1)cnc1OCCCN(CC1)CCN1c(c(NC(C(C(C(F)(F)F)=C1)=CNC1=O)=O)c1)cc(F)c1-c1cnc(N2CCCC2)nc1 XQYUXUMOTAMLEA-UHFFFAOYSA-N 0.000 description 1
- CDBKROHOJVKZNJ-UHFFFAOYSA-N CN(CC1)CCN1c(c(NC(C(C(C(F)(F)F)=C1)=CNC1=O)=O)c1)cc(F)c1-c1cnc(C#N)nc1 Chemical compound CN(CC1)CCN1c(c(NC(C(C(C(F)(F)F)=C1)=CNC1=O)=O)c1)cc(F)c1-c1cnc(C#N)nc1 CDBKROHOJVKZNJ-UHFFFAOYSA-N 0.000 description 1
- XHGDUSOCGSBMTC-UHFFFAOYSA-N CN(CC1)CCN1c(c(NC(C(C(C(F)(F)F)=C1)=CNC1=O)=O)c1)cc(F)c1-c1cnc(NC2CC2)nc1 Chemical compound CN(CC1)CCN1c(c(NC(C(C(C(F)(F)F)=C1)=CNC1=O)=O)c1)cc(F)c1-c1cnc(NC2CC2)nc1 XHGDUSOCGSBMTC-UHFFFAOYSA-N 0.000 description 1
- RRQBQDOLKJVCNU-UHFFFAOYSA-N CN(CC1)CCN1c(c(NC(C(C(C(F)(F)F)=C1)=CNC1=O)=O)c1)cc(F)c1-c1cnc(NC2CCCCC2)nc1 Chemical compound CN(CC1)CCN1c(c(NC(C(C(C(F)(F)F)=C1)=CNC1=O)=O)c1)cc(F)c1-c1cnc(NC2CCCCC2)nc1 RRQBQDOLKJVCNU-UHFFFAOYSA-N 0.000 description 1
- QGDHQOJSPUAKSA-UHFFFAOYSA-N CN(CC1)CCN1c(c(NC(C(C(C(F)(F)F)=C1)=CNC1=O)=O)c1)cc(F)c1-c1cncnc1 Chemical compound CN(CC1)CCN1c(c(NC(C(C(C(F)(F)F)=C1)=CNC1=O)=O)c1)cc(F)c1-c1cncnc1 QGDHQOJSPUAKSA-UHFFFAOYSA-N 0.000 description 1
- MONYSZXYDXDGEK-UHFFFAOYSA-N Cc(nc1)ncc1-c(cc(c(N1CCN(C)CC1)c1)NC(C(C(C(F)(F)F)=C2)=CNC2=O)=O)c1F Chemical compound Cc(nc1)ncc1-c(cc(c(N1CCN(C)CC1)c1)NC(C(C(C(F)(F)F)=C2)=CNC2=O)=O)c1F MONYSZXYDXDGEK-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrrole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662301673P | 2016-03-01 | 2016-03-01 | |
| US62/301,673 | 2016-03-01 | ||
| PCT/CA2017/050269 WO2017147700A1 (en) | 2016-03-01 | 2017-03-01 | Inhibitors of wdr5 protein-protein binding |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2017226004A1 AU2017226004A1 (en) | 2018-09-06 |
| AU2017226004B2 true AU2017226004B2 (en) | 2021-07-22 |
Family
ID=59743306
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2017226004A Ceased AU2017226004B2 (en) | 2016-03-01 | 2017-03-01 | Inhibitors of WDR5 protein-protein binding |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11319299B2 (enExample) |
| EP (1) | EP3423451B1 (enExample) |
| JP (3) | JP7624690B2 (enExample) |
| KR (1) | KR20180120720A (enExample) |
| CN (1) | CN109195965B (enExample) |
| AU (1) | AU2017226004B2 (enExample) |
| BR (1) | BR112018067392A2 (enExample) |
| CA (1) | CA3015406A1 (enExample) |
| CL (1) | CL2018002505A1 (enExample) |
| CO (1) | CO2018010504A2 (enExample) |
| DK (1) | DK3423451T3 (enExample) |
| EA (1) | EA038109B1 (enExample) |
| EC (1) | ECSP18073726A (enExample) |
| IL (1) | IL261472B (enExample) |
| MX (1) | MX2018010374A (enExample) |
| WO (1) | WO2017147700A1 (enExample) |
| ZA (1) | ZA201805879B (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3423451T3 (da) | 2016-03-01 | 2022-11-28 | Propellon Therapeutics Inc | Inhibitorer af wdr5-protein-proteinbinding |
| WO2017147701A1 (en) | 2016-03-01 | 2017-09-08 | Ontario Institute For Cancer Research (Oicr) | Inhibitors of wdr5 protein-protein binding |
| JP2019537585A (ja) | 2016-10-28 | 2019-12-26 | アイカーン スクール オブ メディスン アット マウント シナイ | Ｅｚｈ２媒介性がんを治療するための組成物および方法 |
| CA3045037A1 (en) | 2016-12-08 | 2018-06-14 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating cdk4/6-mediated cancer |
| WO2018176134A1 (en) | 2017-03-27 | 2018-10-04 | HYDRO-QUéBEC | Salts for use in electrolyte compositions or as electrode additives |
| WO2019046944A1 (en) * | 2017-09-06 | 2019-03-14 | Propellon Therapeutics Inc. | INHIBITORS OF PROTEIN BINDING WDR5-PROTEIN |
| US10501466B2 (en) | 2017-09-19 | 2019-12-10 | Vanderbilt University | WDR5 inhibitors and modulators |
| EP3736266A4 (en) * | 2018-01-04 | 2021-01-06 | Peking University Shenzhen Graduate School | COMPOUND SIMULTANEOUSLY INHIBITING THE LSD1 AND HDAC TARGETS AND ITS APPLICATION |
| US11472799B2 (en) | 2018-03-06 | 2022-10-18 | Icahn School Of Medicine At Mount Sinai | Serine threonine kinase (AKT) degradation / disruption compounds and methods of use |
| CN108715585A (zh) * | 2018-04-23 | 2018-10-30 | 中国药科大学 | 苯基联三氮唑类mll1-wdr5蛋白-蛋白相互作用抑制剂 |
| US10844044B2 (en) | 2018-06-14 | 2020-11-24 | Vanderbilt University | WDR5 inhibitors and modulators |
| JP2021527666A (ja) * | 2018-06-21 | 2021-10-14 | アイカーン スクール オブ メディスン アット マウント シナイ | Ｗｄ４０反復ドメインタンパク質５（ｗｄｒ５）分解／破壊化合物および使用の方法 |
| US10807959B2 (en) | 2018-08-16 | 2020-10-20 | Vanderbilt University | WDR5-MLL1 inhibitors and modulators |
| CN109734674B (zh) | 2019-02-26 | 2022-08-26 | 中国药科大学 | 苯胺类wdr5蛋白-蛋白相互作用抑制剂及其制法和用途 |
| CN113543852A (zh) | 2019-03-06 | 2021-10-22 | 第一三共株式会社 | 吡咯并吡唑衍生物 |
| CN114423463B (zh) | 2019-05-06 | 2025-09-26 | 西奈山伊坎医学院 | 作为hpk1的降解剂的异双功能化合物 |
| CN111039860B (zh) * | 2019-12-02 | 2022-09-13 | 河北科技大学 | 2-羟基-n-(4’-氯联苯-2-基)烟酰胺的合成方法及应用 |
| CN113024538B (zh) * | 2019-12-24 | 2022-09-09 | 南开大学 | 吡唑酰胺类化合物及其制备和在防治植物病菌病和杀虫中的应用 |
| US12103924B2 (en) | 2020-06-01 | 2024-10-01 | Icahn School Of Medicine At Mount Sinai | Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use |
| CN114539073A (zh) * | 2022-02-18 | 2022-05-27 | 郑州萃智医药科技有限公司 | 3-溴-2-氯-4,6-二氟苯胺的合成方法 |
| JP2025509830A (ja) * | 2022-03-14 | 2025-04-11 | フヤバイオ インターナショナル，エルエルシー | 血液脳関門を通過するｍｌｌ１－ｗｄｒ５タンパク質間相互作用阻害剤化合物及びそれらの使用 |
| AR129265A1 (es) | 2022-05-12 | 2024-08-07 | Syngenta Crop Protection Ag | Compuestos de alcoxi-heteroaril-carboxamida o tioamida |
| CN119365449A (zh) * | 2022-07-01 | 2025-01-24 | 甘李药业股份有限公司 | 一种用作wdr5抑制剂的化合物或其可药用盐及其应用 |
| EP4554579A2 (en) * | 2022-07-14 | 2025-05-21 | Huyabio International, LLC | Combination therapies of wdr5 inhibitors and pd-1 inhibitors |
| CN115974965B (zh) * | 2022-08-31 | 2025-09-12 | 中国科学技术大学 | 一种靶向wdr5的多肽抑制剂及其用途 |
| CN119143715B (zh) * | 2024-11-12 | 2025-03-14 | 天津匠新致成科技有限公司 | 二芳基团甲基哌嗪类化合物及其制备方法、药物组合物和应用 |
| CN119661474A (zh) * | 2024-12-16 | 2025-03-21 | 中国药科大学 | 一类羟肟酸类的双靶点化合物衍生物及其应用 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1247804A1 (en) | 1993-11-12 | 2002-10-09 | PHARMACIA & UPJOHN COMPANY | Pyrimidine-thioalkyl and alkylether compounds |
| JPH0959236A (ja) | 1995-08-23 | 1997-03-04 | Dai Ichi Seiyaku Co Ltd | ベンズアミド化合物 |
| US20010051719A1 (en) | 1996-12-19 | 2001-12-13 | Smithkline Beecham P.L.C. | Novel compounds |
| US6362371B1 (en) | 1998-06-08 | 2002-03-26 | Advanced Medicine, Inc. | β2- adrenergic receptor agonists |
| DE19952146A1 (de) | 1999-10-29 | 2001-06-07 | Boehringer Ingelheim Pharma | Arylalkane, Arylalkene und Aryl-azaalkane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| HUP0300382A3 (en) | 2000-03-29 | 2006-11-28 | Cyclacel Ltd | 2-substituted 4-heteroaryl-pyrimidines and their use in the treatmetn of proliferative disorders and pharmaceutical compositions containing the compounds |
| JP2002193938A (ja) | 2000-12-01 | 2002-07-10 | Bayer Ag | ４−アリールピリジン誘導体 |
| WO2002088101A2 (en) | 2001-04-27 | 2002-11-07 | Vertex Pharmaceuticals Incorporated | Inhibitors of bace |
| GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| CA2492593A1 (en) | 2002-07-15 | 2004-01-22 | Myriad Genetics, Inc. | Compounds, compositions, and methods employing same |
| WO2004022562A1 (en) | 2002-09-09 | 2004-03-18 | Cellular Genomics, Inc. | 6-ARYL-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINES, METHOD OF MAKING, AND METHOD OF USE THEREOF |
| GB0412072D0 (en) | 2004-05-28 | 2004-06-30 | Syngenta Participations Ag | Chemical compounds |
| CN1960988B (zh) | 2004-06-10 | 2012-01-25 | Irm责任有限公司 | 作为蛋白激酶抑制剂的化合物和组合物 |
| CN101106990B (zh) | 2005-01-26 | 2010-12-08 | Irm责任有限公司 | 用作蛋白激酶抑制剂的化合物和组合物 |
| WO2006124731A2 (en) | 2005-05-12 | 2006-11-23 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| DE102005022977A1 (de) | 2005-05-19 | 2006-12-07 | Merck Patent Gmbh | Phenylchinazolinderivate |
| US20070254894A1 (en) | 2006-01-10 | 2007-11-01 | Kane John L Jr | Novel small molecules with selective cytotoxicity against human microvascular endothelial cell proliferation |
| BRPI0707666A2 (pt) | 2006-02-06 | 2011-05-10 | Irm Llc | compostos e composiÇÕes como inibidores de proteÍna cinase |
| CN102861338A (zh) | 2006-04-05 | 2013-01-09 | 诺瓦提斯公司 | 用于治疗癌症、包含bcr-abl/c-kit/pdgf-r tk抑制剂的组合 |
| ES2431163T3 (es) * | 2007-03-01 | 2013-11-25 | Novartis Ag | Inhibidores de PIM quinasa y métodos para su uso |
| CN101707863A (zh) | 2007-06-15 | 2010-05-12 | Irm责任有限公司 | 蛋白激酶抑制剂及其使用方法 |
| CN101875617B (zh) | 2009-03-23 | 2015-05-20 | 中国医学科学院药物研究所 | 烷氧基取代芳环的氨甲酰基类芳酸化合物及其制法和用途 |
| AU2010244218B2 (en) | 2009-05-07 | 2012-07-19 | Astrazeneca Ab | Substituted 1-cyanoethylheterocyclylcarboxamide compounds 750 |
| EP2558085B1 (en) | 2010-04-16 | 2017-08-30 | Athenex, Inc. | Compositions and methods for the prevention and treatment of cancer |
| EP2627650A2 (en) | 2010-05-26 | 2013-08-21 | Merck Sharp & Dohme Corp. | N-phenyl imidazole carboxamide inhibitors of 3-phosphoinositide-dependent protein kinase-1 |
| WO2011156557A2 (en) | 2010-06-11 | 2011-12-15 | Thomas James B | Compounds active at the neurotensin receptor |
| US9233086B2 (en) * | 2010-06-16 | 2016-01-12 | The Regents Of The University Of Michigan | Inhibition of WDR5 interaction with its binding partners |
| WO2012066065A1 (en) | 2010-11-17 | 2012-05-24 | Novartis Ag | Phenyl-heteroaryl amine compounds and their uses |
| AR091586A1 (es) * | 2012-06-28 | 2015-02-11 | Fujifilm Corp | Derivado de amida o su sal como inhibidor de la produccion de colageno |
| WO2014048878A1 (en) | 2012-09-26 | 2014-04-03 | Evotec (Uk) Ltd. | Phenyl- or pyridyl- pyrrolo[2,3b]pyrazine derivatives useful in the treatment or prevention of proliferative disorders or dysplasia |
| WO2014058071A1 (ja) | 2012-10-12 | 2014-04-17 | 武田薬品工業株式会社 | シクロプロパンアミン化合物およびその用途 |
| US9079866B2 (en) | 2013-02-04 | 2015-07-14 | Janssen Pharmaceutica Nv | Flap modulators |
| JP6879740B2 (ja) | 2013-12-13 | 2021-06-02 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | リンパ形質細胞性リンパ腫を処置する方法 |
| US9908872B2 (en) | 2013-12-13 | 2018-03-06 | Dana-Farber Cancer Institute, Inc. | Methods to treat lymphoplasmacytic lymphoma |
| CN104926801B (zh) * | 2014-03-22 | 2019-06-04 | 浙江大学 | 取代氮杂环类衍生物、含其的药物组合物及其在抗肿瘤中的应用 |
| CN105585565B (zh) | 2014-10-23 | 2019-10-01 | 中国医学科学院药物研究所 | 含2-苯胺基-4-噻唑基吡啶衍生物及其制法和药物组合物与用途 |
| CN105837575B (zh) | 2015-01-13 | 2019-01-15 | 四川大学 | 3-乙炔基吡唑并嘧啶衍生物及其制备方法和用途 |
| CN105175284B (zh) * | 2015-07-21 | 2017-06-16 | 中国药科大学 | 酰胺类化合物、制备方法及其医药用途 |
| DK3423451T3 (da) * | 2016-03-01 | 2022-11-28 | Propellon Therapeutics Inc | Inhibitorer af wdr5-protein-proteinbinding |
| IL302705A (en) | 2016-03-01 | 2023-07-01 | Immatics Biotechnologies Gmbh | Peptides, combinations of peptides, cell-based drugs for use in immunotherapy against bladder cancer and other types of cancer |
| WO2017147701A1 (en) | 2016-03-01 | 2017-09-08 | Ontario Institute For Cancer Research (Oicr) | Inhibitors of wdr5 protein-protein binding |
| WO2017221092A1 (en) | 2016-06-20 | 2017-12-28 | Novartis Ag | Triazolopyridine compounds and uses thereof |
| US10160763B2 (en) | 2016-09-13 | 2018-12-25 | Vanderbilt University | WDR5 inhibitors and modulators |
| WO2019046944A1 (en) | 2017-09-06 | 2019-03-14 | Propellon Therapeutics Inc. | INHIBITORS OF PROTEIN BINDING WDR5-PROTEIN |
| US10501466B2 (en) | 2017-09-19 | 2019-12-10 | Vanderbilt University | WDR5 inhibitors and modulators |
| US11999716B2 (en) | 2018-10-24 | 2024-06-04 | Vanderbilt University | WDR5 inhibitors and modulators |
| WO2021026672A1 (en) | 2019-08-09 | 2021-02-18 | Novartis Ag | Heterocyclic wdr5 inhibitors as anti-cancer compounds |
-
2017
- 2017-03-01 DK DK17759039.5T patent/DK3423451T3/da active
- 2017-03-01 EP EP17759039.5A patent/EP3423451B1/en active Active
- 2017-03-01 MX MX2018010374A patent/MX2018010374A/es unknown
- 2017-03-01 CA CA3015406A patent/CA3015406A1/en active Pending
- 2017-03-01 EA EA201891974A patent/EA038109B1/ru unknown
- 2017-03-01 CN CN201780024229.0A patent/CN109195965B/zh active Active
- 2017-03-01 BR BR112018067392A patent/BR112018067392A2/pt not_active IP Right Cessation
- 2017-03-01 WO PCT/CA2017/050269 patent/WO2017147700A1/en not_active Ceased
- 2017-03-01 KR KR1020187028037A patent/KR20180120720A/ko not_active Ceased
- 2017-03-01 JP JP2018546618A patent/JP7624690B2/ja active Active
- 2017-03-01 US US16/080,866 patent/US11319299B2/en active Active
- 2017-03-01 AU AU2017226004A patent/AU2017226004B2/en not_active Ceased
-
2018
- 2018-08-29 IL IL261472A patent/IL261472B/en unknown
- 2018-08-31 ZA ZA2018/05879A patent/ZA201805879B/en unknown
- 2018-08-31 CL CL2018002505A patent/CL2018002505A1/es unknown
- 2018-09-28 CO CONC2018/0010504A patent/CO2018010504A2/es unknown
- 2018-10-01 EC ECSENADI201873726A patent/ECSP18073726A/es unknown
-
2022
- 2022-02-25 JP JP2022028700A patent/JP2022071046A/ja active Pending
- 2022-05-06 US US17/738,707 patent/US12264147B2/en active Active
-
2024
- 2024-04-25 JP JP2024071190A patent/JP2024102151A/ja active Pending
Non-Patent Citations (1)
| Title |
|---|
| FLORIAN GREBIEN et al., "Pharmacological targeting of the Wdr5-MLL interaction in C/EBPalpha N-terminal leukemia", Nat Chem Biol., 2015, vol. 11, no. 8, pages 571 - 578 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CL2018002505A1 (es) | 2019-01-04 |
| JP2022071046A (ja) | 2022-05-13 |
| EP3423451B1 (en) | 2022-08-17 |
| MX2018010374A (es) | 2019-03-28 |
| JP7624690B2 (ja) | 2025-01-31 |
| IL261472B (en) | 2022-01-01 |
| IL261472A (en) | 2018-10-31 |
| CA3015406A1 (en) | 2017-09-08 |
| US11319299B2 (en) | 2022-05-03 |
| US20190112290A1 (en) | 2019-04-18 |
| CN109195965A (zh) | 2019-01-11 |
| ECSP18073726A (es) | 2018-11-30 |
| CO2018010504A2 (es) | 2018-12-14 |
| EP3423451A4 (en) | 2019-09-04 |
| CN109195965B (zh) | 2022-07-26 |
| ZA201805879B (en) | 2021-04-28 |
| US20230219926A1 (en) | 2023-07-13 |
| EA038109B1 (ru) | 2021-07-07 |
| KR20180120720A (ko) | 2018-11-06 |
| JP2019512482A (ja) | 2019-05-16 |
| WO2017147700A1 (en) | 2017-09-08 |
| DK3423451T3 (da) | 2022-11-28 |
| US12264147B2 (en) | 2025-04-01 |
| AU2017226004A1 (en) | 2018-09-06 |
| BR112018067392A2 (pt) | 2019-01-02 |
| JP2024102151A (ja) | 2024-07-30 |
| EP3423451A1 (en) | 2019-01-09 |
| EA201891974A1 (ru) | 2019-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2017226004B2 (en) | Inhibitors of WDR5 protein-protein binding | |
| ES2950881T3 (es) | 1H-imidazo[4,5-b]piridin-2(3H)-onas sustituidas y su uso como moduladores receptores GLUN2B | |
| ES2654288T3 (es) | Moduladores de P2X7 | |
| JP2020143124A (ja) | Ｕｓｐ３０阻害剤としての１−シアノ−ピロリジン化合物 | |
| EP3066093B9 (en) | Gsk-3 inhibitors | |
| CN112638373A (zh) | 细胞周期蛋白依赖性激酶抑制剂 | |
| ES2781867T3 (es) | 4-Azaindoles sustituidos y su utilización como moduladores del receptor GluN2B | |
| AU2018331456A1 (en) | Pyrazolopyrimidinone compounds and uses thereof | |
| US10239873B2 (en) | 7-azaindole or 4,7-diazaindole derivatives as IKKϵ epsilon and TBK1 inhibitor and pharmaceutical composition comprising same | |
| EP3423437A1 (en) | Inhibitors of wdr5 protein-protein binding | |
| CN114144230A (zh) | 作为eed和prc2调节剂的大环唑并吡啶衍生物 | |
| CN114401955A (zh) | 细胞周期蛋白依赖性激酶的抑制剂 | |
| WO2012064269A1 (en) | COMPOUNDS AND THEIR USE FOR TREATMENT OF Αβ-RELATED DISEASES | |
| WO2017073743A1 (ja) | 三環性化合物 | |
| CN112689636A (zh) | 新型杂原子芳香族酰胺衍生物以及含有其的药剂 | |
| KR20190085112A (ko) | Gsk-3 억제제 | |
| HK40048972A (en) | Inhibitors of cyclin-dependent kinases | |
| HK40046970A (en) | Novel heteroaromatic amide derivative and medicine containing same | |
| HK1232216B (en) | P2x7 modulators | |
| HK1218652B (en) | P2x7 modulators |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |